Refine your search:     
Report No.
 - 

Production of no-carrier-added $$^{177}$$Lu for radioimmunotherapy

Watanabe, Satoshi; Hashimoto, Kazuyuki; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko

Lutetium-177 is considered to have potential for application in radioimmunotherapy, because it emits $$beta$$-particles (E$$_{max}$$=498 keV) suitable to penetrate small tumors and its physical half-life of 6.734 days is long enough for $$^{177}$$Lu-labeled antibodies to accumulate to tumor sites. In addition, real time imaging of biodistribution can be done by using the $$^{177}$$Lu, because the energy of $$gamma$$-rays (113 keV and 208 keV) emitted from $$^{177}$$Lu is particularly suitable for imaging by single photon emission computed tomography. We can produce $$^{177}$$Lu by the $$^{176}$$Lu (n,$$gamma$$) $$^{177}$$Lu process and the $$^{176}$$Yb(n,$$gamma$$) $$^{177}$$Yb (T$$_{1/2}$$=1.911 h)$$rightarrow$$$$^{177}$$Lu process. In the field of radioimmunotherapy using labeled monoclonal antibodies, to enhance the effect of therapy, no-carrier-added (nca) $$^{177}$$Lu produced in the $$^{176}$$Yb(n,$$gamma$$) $$^{177}$$Yb (T$$_{1/2}$$=1.911 h) $$rightarrow$$$$^{177}$$Lu process with high specific radioactivity are required. Therefore, in the present paper, production of highly-purified nca $$^{177}$$Lu from macroscopic amounts of the ytterbium target is developed.

Accesses

:

- Accesses

InCites™

:

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.